Solid Pseudopapillary Neoplasms of the Pancreas: Clinicopathologic Analysis and a Predictive Model

Chen, Jingci; Zong, Liju; Wang, Pengyan; Liu, Yilin; Zhang, Hongkai; Chang, Xiaoyan; Lu, Zhaohui; Li, Wencai; Ma, Yihui; Yu, Shuangni; Chen, Jie

doi:10.1016/j.modpat.2023.100141

Cited by 16 publications

(28 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Choi [26] found that the pediatric group had larger tumors than the adult group, but the survival rate of the pediatric group was excellent. Chen [27] reported that children accounted for 38.1% of the recurrence cases, which was higher than that of other age groups. In our study, the proportion of tumors ≥ 5 cm and the proportion of tumors with a Ki-67 proliferation index ≥ 5% in the pediatric group were signi cantly higher than those in the other two groups.…”

Section: Discussionmentioning

confidence: 90%

Analyses of CTNNB1 mutation, β-catenin expression and clinicopathological characteristics in 179 cases of solid-pseudopapillary neoplasm of the pancreas

Zhao,

Wang,

et al. 2023

Preprint

View full text Add to dashboard Cite

Solid-pseudopapillary neoplasm (SPN) of the pancreas is a low-grade malignant tumour, that mainly affects young females. Given its typical clinical characteristics, histopathological morphology and immunohistochemical nuclear expression of β-catenin, it is usually not difficult to diagnose SPN. However, nuclear expression of β-catenin is occasionally negative or false negative in SPN, leading to a missed diagnosis. In this study, we aimed to investigate the clinical significance of CTNNB1 mutation detection for diagnosing SPN and explore the difference in clinicopathological characteristics between female and male patients at different ages. We detected point mutations in exon 3 of CTNNB1 in 74.3% (133/179) of SPNs by Sanger sequencing. The main mutation sites were D32 (26%), S33 (23%), S37 (21%), G34 (14%) and T41 (11%). In the 3 SPNs without nuclear expression of β-catenin, Sanger sequencing showed the S33C mutation in exon 3 of CTNNB1 in two cases but not in one case in which next-generation sequencing detected the S37C mutation. Therefore, for atypical cases, testing for CTNNB1 mutations can help in the accurate diagnosis of SPN. The median age of the 179 patients was 31 years (6 ~ 64 years), and there were 32 male patients (17.9%) in this cohort. The tumour size, Ki-67 index, and the negative rates of β-catenin nuclear expression and syn expression in the paediatric group were higher than those in youth group and old group (P < 0.05 for all). There was no significant difference in age, tumour site; tumour size; expression of β-catenin, CD10, PR, Vimentin or Syn; Ki-67 index; or proportion of CTNNB1 mutations between male and female patients (P < 0.05 for all). Compared with middle-aged and elderly patients, paediatric with SPN may be more prone to recurrence, and their immunohistochemical phenotype is more complex, requiring additional care in the diagnosis and postoperative follow-up.

show abstract

Section: Discussionmentioning

confidence: 90%

Analyses of CTNNB1 mutation, β-catenin expression and clinicopathological characteristics in 179 cases of solid-pseudopapillary neoplasm of the pancreas

Zhao,

Wang,

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In 2010, all SPNs have been re‐classified as low‐grade malignant tumours, and in 2019, an extremely aggressive subtype was designated as SPN with high‐grade malignant transformation. Generally, SPNs have an excellent overall survival with 5‐ and 10‐year relapse‐free survival (RFS) rates reported to be 97.4% and 90.2%, respectively 3–5 . Studies have shown that even advanced stage SPNs have excellent prognosis.…”

Section: Discussionmentioning

confidence: 99%

“…rates reported to be 97.4% and 90.2%, respectively. [3][4][5] Studies have shown that even advanced stage SPNs have excellent prognosis. A meta-analysis by Hao et al showed the 5-and 10-year survival rates for advanced stage SPNs were 71.1% and 65.5%, respectively.…”

Section: A S E Pr E S E Ntati O Nmentioning

confidence: 99%

Solid pseudopapillary neoplasm of pancreas with liver metastasis, diagnosed on fine needle aspiration cytology (FNAC)

Ahsan,

Khan,

Zhang

2024

Cytopathology

View full text Add to dashboard Cite

show abstract

“…Solid pseudopapillary neoplasm is a rare pancreatic neoplasm with an uncertain etiopathogenesis 1,2 . Its clinical presentation is not specific.…”

Section: Discussionmentioning

confidence: 99%

“…Solid pseudopapillary neoplasm is a rare pancreatic neoplasm with an uncertain etiopathogenesis. 1 , 2 Its clinical presentation is not specific. The definitive diagnosis of SPN relies on histopathological examination coupled with an immunohistochemical study.…”

Section: Discussionmentioning

confidence: 99%

A rare pancreatic neoplasm in a 40‐year‐old male patient

Limaïem

Hajri

2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical Message The differential diagnoses of solid pseudopapillary neoplasm of the pancreas include cystic pancreatic neuroendocrine tumor, acinar cell carcinoma, and pancreatoblastoma. Abstract Solid pseudopapillary neoplasm (SPN) is a low‐grade malignant pancreatic tumor which accounts for 0.9%–2.7% of all exocrine pancreatic neoplasms. It predominantly affects young females (90%) and less frequently occurs in male patients. Its prognosis after surgical resection remains excellent. Herein, we report a case of SPN in a male patient.

show abstract

Solid Pseudopapillary Neoplasms of the Pancreas: Clinicopathologic Analysis and a Predictive Model

Cited by 16 publications

References 38 publications

Analyses of CTNNB1 mutation, β-catenin expression and clinicopathological characteristics in 179 cases of solid-pseudopapillary neoplasm of the pancreas

Analyses of CTNNB1 mutation, β-catenin expression and clinicopathological characteristics in 179 cases of solid-pseudopapillary neoplasm of the pancreas

Solid pseudopapillary neoplasm of pancreas with liver metastasis, diagnosed on fine needle aspiration cytology (FNAC)

A rare pancreatic neoplasm in a 40‐year‐old male patient

Contact Info

Product

Resources

About